Literature DB >> 9285644

Ischemic preconditioning prevents the impairment of hypoxic coronary vasodilatation caused by ischemia/reperfusion: role of adenosine A1/A3 and bradykinin B2 receptor activation.

E Giannella1, H C Mochmann, R Levi.   

Abstract

We previously reported that hypoxic coronary vasodilatation (HCVD) is initiated by endothelial NO and sustained by adenosine. Prolonged ischemia/reperfusion impairs endothelium-dependent coronary vasodilatation, whereas transient ischemia (ie, preconditioning) protects the myocardium from subsequent ischemic events. Accordingly, we assessed whether prolonged ischemia/reperfusion impairs HCVD and whether preconditioning prevents this dysfunction. HCVD, elicited in isolated guinea pig hearts by a 1-minute exposure to 100% N2, consisted of an approximately 70% increase in coronary flow associated with enhanced nitrite/nitrate and adenosine overflow (+40% and 5-fold, respectively). After 30-minute global ischemia and 20-minute reperfusion, HCVD was decreased by approximately 60%, and the increases in nitrite/nitrate and adenosine overflow were abolished. Preconditioning (ie, three cycles of 5-minute global ischemia+5-minute reperfusion) prevented the impairment of HCVD and fully restored the increase in nitrite/nitrate overflow, but not that of adenosine. The protective effect of preconditioning was mimicked by perfusion with the adenosine A1 receptor agonist N6-cyclopentyladenosine and prevented by the A1 receptor antagonist N-0861. In addition, the A3 receptor agonist N6-(3-iodobenzyl)adenosine-5'-N-methyl-carboxamide had a similar protective effect. The bradykinin B2 receptor antagonist HOE 140 abolished the protective effect of preconditioning, whereas the NO synthase inhibitor N(omega)-methyl-L-arginine and the cycloxygenase inhibitor indomethacin did not. Our data indicate that preconditioning restores HCVD by a process that is triggered by activation of adenosine A1/A3 and bradykinin B2 receptors. The action of bradykinin is independent of NO and prostacyclin production. Once restored by preconditioning, HCVD is mediated by NO but no longer sustained by adenosine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9285644     DOI: 10.1161/01.res.81.3.415

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  9 in total

Review 1.  Organ preconditioning: the past, current status, and related lung studies.

Authors:  Shi-ping Luh; Pan-chyr Yang
Journal:  J Zhejiang Univ Sci B       Date:  2006-05       Impact factor: 3.066

Review 2.  Kinin receptors.

Authors:  F Marceau; D R Bachvarov
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

3.  Reperfusion-induced coronary endothelial injury: A new target for ischemic preconditioning.

Authors:  K Laude; C Thuillez; V Richard
Journal:  Exp Clin Cardiol       Date:  2001

4.  Aldehyde dehydrogenase activation prevents reperfusion arrhythmias by inhibiting local renin release from cardiac mast cells.

Authors:  Kenichiro Koda; Mariselis Salazar-Rodriguez; Federico Corti; Noel Yan-Ki Chan; Racha Estephan; Randi B Silver; Daria Mochly-Rosen; Roberto Levi
Journal:  Circulation       Date:  2010-08-09       Impact factor: 29.690

Review 5.  Purinergic signaling in myocardial ischemia-reperfusion injury.

Authors:  Yi Zhuang; Mei-Ling Yu; Sheng-Feng Lu
Journal:  Purinergic Signal       Date:  2022-03-07       Impact factor: 3.765

6.  Intestinal ischemic preconditioning after ischemia/reperfusion injury in rat intestine: profiling global gene expression patterns.

Authors:  Stacey D Moore-Olufemi; Shodimu-Emmanuel Olufemi; Steve Lott; Norio Sato; Rosemary A Kozar; Frederick A Moore; Ravi S Radhakrishnan; Shinil Shah; Fernando Jimenez; Bruce C Kone; Charles S Cox
Journal:  Dig Dis Sci       Date:  2009-09-25       Impact factor: 3.199

7.  Pretreatment with bone morphogenetic protein-7 (BMP-7) mimics ischemia preconditioning following intestinal ischemia/reperfusion injury in the intestine and liver.

Authors:  Ravi S Radhakrishnan; Geetha L Radhakrishnan; Hari R Radhakrishnan; Hasen Xue; Sasha D Adams; Stacey D Moore-Olufemi; Matthew T Harting; Charles S Cox; Bruce C Kone
Journal:  Shock       Date:  2008-11       Impact factor: 3.454

Review 8.  Evidence and evidence gaps of medical treatment of non-tumorous diseases of the head and neck.

Authors:  Murat Bas
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2016-12-15

9.  Acute hyperglycemia abolishes ischemic preconditioning by inhibiting Akt phosphorylation: normalizing blood glucose before ischemia restores ischemic preconditioning.

Authors:  Zequan Yang; Yikui Tian; Yuan Liu; Sara Hennessy; Irving L Kron; Brent A French
Journal:  Oxid Med Cell Longev       Date:  2013-11-25       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.